Filing Flows › Starling Oncology (STLN) › Guidance & outlook
Starling Oncology (STLN) guidance and outlook
Starling Oncology (STLN) raised some and lowered other parts of its guidance on Nov 5, 2026: EBITDA $3.0M–$5.0M for Q4 2026; Revenue $650M–$660M for FY2026; Gross profit $107M–$110M for FY2026; EBITDA $4.0M–$6.0M for FY2026. Starling Oncology's 10-Q filed Nov 6, 2026 makes 9 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | +40% | new |
| EBITDA | Q4 2026 | $3.0M–$5.0M | new |
| Revenue | FY2026 | $650M–$660M | lowered |
| Gross profit | FY2026 | $107M–$110M | raised |
| EBITDA | FY2026 | $4.0M–$6.0M | raised |
| Free cash flow | FY2026 | $5.0M–$10.0M | lowered |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 6, 2026
- The Company records revenue net of an allowance for contractual adjustments, which represents the net revenue expected to be collected from third-party payors (including managed care, commercial, and governmental payors such as Medicare and Medicaid), and patients.
- General and administrative expenses are expected to increase over time, due to the legal, accounting, insurance, investor relations and other costs that the Company incurs as a public company, as well as other costs associated with continuing to grow the business.
- While the Company expects its selling, general and administrative expenses to increase in absolute dollars in the foreseeable future. such expenses are on average expected to decrease as a percentage of revenue over the long term.
- The Company includes Adjusted EBITDA because it is an important measure which our management uses to assess the results of operations, to evaluate factors and trends affecting the business, and to plan and forecast future periods.
- (3) Consulting fees were comprised of a subset of the Company’s total consulting fees primarily related to certain non-recurring advisory projects during the three months ended September 30, 2026 and 2025.
- (3) Consulting fees were comprised of a subset of the Company’s total consulting fees primarily related to certain non-recurring advisory projects during the nine months ended September 30, 2026 and 2025
- The Company recognizes consolidated revenue based upon the principle of the transfer of control of our goods and services to customers in an amount that reflects the consideration to which it expects to be entitled.
- We will continue to reevaluate the continued need for a valuation allowance.
- When circumstances indicate that recoverability may be impaired, the Company assesses its ability to recover the carrying value of the asset group from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations.
Starling Oncology's latest quarter
Starling Oncology, Q3 2026: revenue $170M (+24% year over year), operating margin -1.8%, net loss $15.7M, operating cash flow $10.1M. The chart follows the revenue to costs, profit and cash.
Questions
Did Starling Oncology raise or lower its guidance?
Starling Oncology (STLN) raised some and lowered other parts of its guidance on Nov 5, 2026: EBITDA $3.0M–$5.0M for Q4 2026; Revenue $650M–$660M for FY2026; Gross profit $107M–$110M for FY2026; EBITDA $4.0M–$6.0M for FY2026.
What does Starling Oncology expect?
The Company records revenue net of an allowance for contractual adjustments, which represents the net revenue expected to be collected from third-party payors (including managed care, commercial, and governmental payors such as Medicare and Medicaid), and patients. General and administrative expenses are expected to increase over time, due to the legal, accounting, insurance, investor relations and other costs that the Company incurs as a public company, as well as other costs associated with continuing to grow the business. While the Company expects its selling, general and administrative exp
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.